167 related articles for article (PubMed ID: 23337026)
21. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
Beau-Faller M; Degeorges A; Rolland E; Mounawar M; Antoine M; Poulot V; Mauguen A; Barbu V; Coulet F; Prétet JL; Bièche I; Blons H; Boyer JC; Buisine MP; de Fraipont F; Lizard S; Olschwang S; Saulnier P; Prunier-Mirebeau D; Richard N; Danel C; Brambilla E; Chouaid C; Zalcman G; Hainaut P; Michiels S; Cadranel J
J Thorac Oncol; 2011 Jun; 6(6):1006-15. PubMed ID: 21532509
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
Bozzetti C; Negri FV; Azzoni C; Naldi N; Nizzoli R; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Silini EM; Ardizzoni A
Diagn Cytopathol; 2013 Jul; 41(7):595-8. PubMed ID: 22833420
[TBL] [Abstract][Full Text] [Related]
23. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.
Girard N; Deshpande C; Azzoli CG; Rusch VW; Travis WD; Ladanyi M; Pao W
Chest; 2010 Jan; 137(1):46-52. PubMed ID: 19376842
[TBL] [Abstract][Full Text] [Related]
24. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
[TBL] [Abstract][Full Text] [Related]
25. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
[TBL] [Abstract][Full Text] [Related]
26. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.
Billah S; Stewart J; Staerkel G; Chen S; Gong Y; Guo M
Cancer Cytopathol; 2011 Apr; 119(2):111-7. PubMed ID: 21400670
[TBL] [Abstract][Full Text] [Related]
27. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
28. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
[TBL] [Abstract][Full Text] [Related]
29. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis.
Fassina A; Gazziero A; Zardo D; Corradin M; Aldighieri E; Rossi GP
J Clin Pathol; 2009 Dec; 62(12):1096-102. PubMed ID: 19640859
[TBL] [Abstract][Full Text] [Related]
30. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
31. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
33. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
[TBL] [Abstract][Full Text] [Related]
34. KRAS mutation: should we test for it, and does it matter?
Roberts PJ; Stinchcombe TE
J Clin Oncol; 2013 Mar; 31(8):1112-21. PubMed ID: 23401440
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.
Wang S; Wang Z
Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):30-9. PubMed ID: 25445553
[TBL] [Abstract][Full Text] [Related]
36. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
37. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
Riely GJ; Johnson ML; Medina C; Rizvi NA; Miller VA; Kris MG; Pietanza MC; Azzoli CG; Krug LM; Pao W; Ginsberg MS
J Thorac Oncol; 2011 Aug; 6(8):1435-7. PubMed ID: 21847063
[TBL] [Abstract][Full Text] [Related]
38. EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis.
Han C; Ma J; Zhao J; Zhou Y; Jing W; Zou H
Cancer Invest; 2011 Nov; 29(9):626-34. PubMed ID: 22011285
[TBL] [Abstract][Full Text] [Related]
39. Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features?
Glynn C; Zakowski MF; Ginsberg MS
J Thorac Oncol; 2010 Mar; 5(3):344-8. PubMed ID: 20087229
[TBL] [Abstract][Full Text] [Related]
40. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
